Predicting nasal high-flow therapy failure by pediatric respiratory rate-oxygenation index and pediatric respiratory rate-oxygenation index variation in children

Yildizdas D., YÖNTEM A., Iplik G., ÖZGÜR HOROZ Ö., EKİNCİ F.

EUROPEAN JOURNAL OF PEDIATRICS, vol.180, no.4, pp.1099-1106, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 180 Issue: 4
  • Publication Date: 2021
  • Doi Number: 10.1007/s00431-020-03847-6
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.1099-1106
  • Keywords: High-flow nasal cannula, Children, Acute respiratory failure, P-ROXI, P-ROXV, CANNULA, MANAGEMENT, INFANTS
  • Çukurova University Affiliated: Yes


The primary objective of this study was to evaluate whether pediatric respiratory rate-oxygenation index (p-ROXI) and variation in p-ROXI (p-ROXV) can serve as objective markers in children with high-flow nasal cannula (HFNC) failure. In this prospective, single-center observational study, all patients who received HFNC therapy in the general pediatrics ward, pediatric intensive care unit, and the pediatric emergency department were included. High-flow nasal cannula success was achieved for 116 (88.5%) patients. At 24 h, if both p-ROXI and p-ROXV values were above the cutoff point (>= 66.7 and >= 24.0, respectively), HFNC failure was 1.9% and 40.6% if both were below their values (p < 0.001). At 48 h of HFNC initiation, if both p-ROXI and p-ROXV values were above the cutoff point (>= 65.1 and >= 24.6, respectively), HFNC failure was 0.0%; if both were below these values, HFNC failure was 100% (p < 0.001).